Download video

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

850 views

VJHemOnc – Video Journal of Hematology & HemOnc

2 years ago

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
1:36
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Venetoclax and Ibrutinib for CLL
18:01
Venetoclax and Ibrutinib for CLL
by Haematology, Morphology and FRCPath Exams
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-...
4:39
The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-...
by ecancer
Ibrutinib, Venetoclax \& Obinutuzumab to Treat Chronic Lymphocytic Leukemia (CLL) - Dr. Woyach
15:16
Ibrutinib, Venetoclax \& Obinutuzumab to Treat Chronic Lymphocytic Leukemia (CLL) - Dr. Woyach
by CLL Society
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
1:25
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
by OncLive
Ibrutinib + Venetoclax for CLL
3:01
Ibrutinib + Venetoclax for CLL
by OncLive
Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL
5:21
Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL
by ecancer
Ibrutinib plus venetoclax followed by MRD-guided ibrutinib plus obinutuzumab in first line CLL
4:36
Ibrutinib plus venetoclax followed by MRD-guided ibrutinib plus obinutuzumab in first line CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
2:43
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
1:46
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
Venetoclax-Obinutuzumab for Chronic Lymphocytic Leukaemia-CLL
24:54
Venetoclax-Obinutuzumab for Chronic Lymphocytic Leukaemia-CLL
by Haematology, Morphology and FRCPath Exams
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
1:36
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
ASH CLL highlights: ibrutinib-venetoclax combination \& undetectable MRD in IGHV-mutated patients
1:47
ASH CLL highlights: ibrutinib-venetoclax combination \& undetectable MRD in IGHV-mutated patients
by VJHemOnc – Video Journal of Hematology \& HemOnc
Venetoclax + Obinutuzumab: Impact on CLL Management
7:29
Venetoclax + Obinutuzumab: Impact on CLL Management
by OncLive
EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
10:20
EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
by Oncoletter
Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL
1:13
Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL
by OncLive
GLOW: Assessing ibrutinib plus venetoclax in CLL
1:54
GLOW: Assessing ibrutinib plus venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc